PAVmed Closes Oversubscribed Rights Offering for Gross Proceeds of $10,350,000
June 12 2018 - 4:05PM
Business Wire
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or
“PAVmed”), a highly differentiated, multiproduct medical device
company, today announced the closing of its oversubscribed equity
subscription rights offering (the “Rights Offering”), which raised
the maximum gross proceeds of $10,350,000.
Pursuant to the Rights Offering, PAVmed’s stockholders exercised
and the Company accepted equity subscription rights resulting in
the issuance of 9 million units that consisted of one share of
common stock and one Series Z Warrant. Each right entitled the
holder to purchase one unit at a subscription price of $1.15 per
unit, with each unit consisting of one share of common stock
(Nasdaq: PAVM) and one Series Z Warrant (Nasdaq: PAVMZ) to purchase
one share of common stock with an exercise price of $1.60. The
Series Z Warrants expire on April 30, 2024 and have certain volume
and price redemption features. The units will immediately split
into their underlying securities and the common stock and the
Series Z Warrants will be immediately tradeable upon their
issuance.
Investors who participated in the Rights Offering should expect
to see the purchased securities in their account within the next
three business days. Additionally, the balance of funds that were
not allocated due to the oversubscription of the Rights Offering
will be returned to participants via the method the participant
used to fund its subscription within the next three business
days.
PAVmed engaged Maxim Group LLC and Dawson James Securities, Inc.
as dealer-managers in the Rights Offering. Questions about the
Rights Offering may be directed to Maxim Group LLC at 405 Lexington
Avenue, New York, NY 10174, Attention Syndicate Department, or via
email at syndicate@maximgrp.com or telephone at (212) 895-3745, or
to Dawson James Securities, Inc., Attention: Prospectus Department,
1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, via email
at mmaclaren@dawsonjames.com or telephone (toll free) at (866)
928-0928.
The Rights Offering was made by means of a written prospectus
pursuant to the Company’s effective registration statement on Form
S-1 (File No. 333-222581) as filed with the SEC. The registration
statement was declared effective by the SEC on May 23, 2018 and is
available on the SEC’s web site at http://www.sec.gov. Copies
of the written prospectus for the Rights Offering may be obtained
by contacting Morrow Sodali Global LLC, the Information Agent for
the Rights Offering, at:
Stockholders please call toll-free: (800)
662-5200Banks and Brokerage Firms please call: (203) 658-9400Email:
PAVM.info@morrowsodali.com
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor will there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About PAVmed
PAVmed Inc. is a highly differentiated, multiproduct medical
device company employing a unique business model designed to
advance innovative products to commercialization much more rapidly
and with significantly less capital than the typical medical device
company. This proprietary model enables PAVmed to pursue an
expanding pipeline strategy with a view to enhancing and
accelerating value creation. PAVmed’s diversified pipeline of
products address unmet clinical needs encompassing a broad spectrum
of clinical areas with attractive regulatory pathways and market
opportunities. Its four lead products provide groundbreaking
approaches to carpal tunnel syndrome (CarpX™), precancerous
conditions of the esophagus (EsoCheck), vascular access (PortIO™)
and pediatric ear infections (DisappEAR™). The company is also
developing innovative products in other areas, such as medical
infusions and tissue ablation, while seeking to further expand its
pipeline through engagements with clinician innovators and leading
academic medical centers. For further information, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements, based upon the current beliefs and expectations of the
Company’s management, are subject to risks and uncertainties, which
could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences
include, among other things, the Company’s ability to complete the
Rights Offering; volatility in the price of the Company’s common
stock; the uncertainties inherent in research and development,
including the cost and time required advance our products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from our preclinical
studies; whether and when our products are cleared by regulatory
authorities; market acceptance of our products once cleared and
commercialized; our ability to raise additional funding and other
competitive developments. PAVmed has not yet received clearance
from the FDA or other regulatory body to market any of its
products. New risks and uncertainties may arise from time to time
and are difficult to predict. All of these factors are difficult or
impossible to predict accurately and many of them are beyond our
control. For a further list and description of these and other
important risks and uncertainties that may affect our future
operations, see Part I, Item IA, “Risk Factors,” in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, as the same may be updated in Part II, Item 1A, “Risk
Factors” in any Quarterly Reports on Form 10-Q filed by us after
our most recent Annual Report. We disclaim any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in our expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180612006263/en/
InvestorsLHA Investor RelationsKim
Sutton Golodetz, 212-838-3777kgolodetz@lhai.comorMediaPAVmed Inc.212-949-4319info@pavmed.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Sep 2023 to Sep 2024